Physician profile
John Michael Halwig
NPI 1841230760
$4,947.77
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,043 · 2020: $1,269 · 2021: $1,169 · 2022: $1,466.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Octapharma USA, INC. | $812.45 | 2020-2022 | |
| Regeneron Healthcare Solutions, INC. | $682.04 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $575.95 | 2020-2022 | |
| Glaxosmithkline, LLC. | $463.26 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $415.18 | 2019-2022 | |
| Genzyme Corporation | $293.66 | 2019-2022 | |
| Biocryst US Sales Co., LLC | $252.65 | 2021-2022 | |
| Pfizer INC. | $157.13 | 2019-2022 | |
| Shire North American Group INC | $154.89 | 2019 | |
| Abbvie INC. | $154.32 | 2021-2022 | |
| Csl Behring | $139.11 | 2019-2022 | |
| Kaleo, INC. | $124.93 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $118.76 | 2019-2021 | |
| Covis Pharma Gmbh | $94.81 | 2019-2020 | |
| Amgen INC. | $92.38 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $84.86 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $72.74 | 2019-2022 | |
| Optinose US, INC. | $67.26 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $43.28 | 2020-2021 | |
| Pharming Healthcare, INC. | $39.69 | 2020-2022 | |
| Alk-Abello, INC | $34.01 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $19.55 | 2020 | |
| Grifols USA, LLC | $19.06 | 2022 | |
| Leo Pharma INC. | $18.20 | 2022 | |
| Aimmune Therapeutics, INC. | $17.60 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Halwig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.